chronic kidney disease
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.
-
Individuals Living with Kidney Disease Deserve More From Our Healthcare System
Policymakers must work to increase access to the Medicare Kidney Disease Education Benefit and expand the Medicare annual wellness benefit to include kidney disease screening. These reforms will catch disease at earlier stages and equip patients to better recognize their risk.
-
Novartis Kidney Disease Drug Hits First Goal of Study; 2024 FDA Filing Planned
Novartis’s iptacopan met the first of two main goals in its pivotal study in immunoglobulin A nephropathy, and the pharma giant plans to seek accelerated FDA approval next year. The drug could challenge two available therapies for the rare kidney disorder.
-
Once a Blockbuster Prospect, Is Travere’s Kidney Drug on Track to Become a Bust?
Seven months after Travere Therapeutics’ flagship drug received accelerated FDA approval in a rare kidney disease, the molecule has fallen short of the key goal of its confirmatory test. It’s the small molecule’s second Phase 3 failure this year.
-
Strive Health, Oak Street Health Strike Kidney Care Partnership
Kidney care company Strive Health announced last week that it is collaborating with primary care company Oak Street Health to serve Medicare members with stage 4 chronic kidney disease and end-stage kidney disease.
-
Humana Taps Interwell Health for Kidney Care
In a new agreement, Interwell Health will provide care to Humana Medicare Advantage HMO and PPO members with chronic kidney disease in 13 states. It will also serve patients with end-stage kidney disease across the country.
-
Emergency Dialysis: A Crutch for Fee-For-Service Healthcare
Physicians often diagnose patients with chronic kidney disease (CKD) too late in the process, when dialysis is the only option left. This isn’t negligence on the part of physicians — it’s simply a consequence of a fee-for-service (FFS) healthcare model that works against patients’ financial well-being and deemphasizes preventative care.
-
Signify Health Unveils Chronic Kidney Disease Evaluation
Home care company Signify Health announced Tuesday that it added an in-home kidney health evaluation to its platform. Based on the results of the evaluation, the company can refer patients to their primary care physician or a specialist if they’re in need of further treatment.
-
Navigating Healthcare’s Data Revolution: Priorities, Opportunities, and Challenges for Health Systems
Arcadia recently partnered with HIMSS Market Insights to survey executives, IT, technology, and clinical leaders. Here’s what we found.
-
MedCity Influencers, Artificial Intelligence
The Case for Automatic Surveillance during Dialysis
This lack of monitoring is a serious problem—both for patients and for the overall healthcare system. The data show that in a typical dialysis center, each patient will suffer an average of 1.7 access blockages per year.
-
GSK Gets FDA Nod for Drug Treating Anemia From Chronic Kidney Disease
The FDA approved GSK drug Jesduvroq for treating anemia in patients with chronic kidney disease. The once-daily pill is the first oral medicine to pass FDA muster in this indication, giving patients a more convenient alternative to injectable anemia therapies.
-
Lessons learned from prison and dialysis while trying to prevent the pain, loss and cost of kidney diseases
These two health care settings provided invaluable lessons: get ahead of the curve through collaboration with other doctors, better monitoring, early referrals, and education.
-
MedCity Influencers, BioPharma, Opinion
Is the HIF-PHI class of next-generation kidney drugs doomed in the U.S.?
Kidney disease patients need access to innovative therapies to expand treatment choices and improve quality of life. The FDA should closely examine whether it is applying the appropriate benefit/risk assessment for new drugs intended for this population.
-
MedCity Influencers, Devices & Diagnostics
The medtech industry’s responsibility in addressing the socioeconomic barriers to accessing and succeeding on renal replacement therapy
Aside from rallying for more patient-oriented reimbursement and removing the red tape involved so that providers can provide home-based dialysis care, medical device manufacturers must also offer a turnkey solution for home-based therapy that includes servicing the device in a door-to-door model.
-
Claiming Akebia agreement breach, Otsuka seeks to end anemia drug pact
Otsuka Pharmaceutical is ending its alliance with Akebia Therapeutics, a move that comes less than two months after the FDA rejected their partnered anemia drug, vadadustat, and asked for another clinical trial. Otsuka alleges unspecified breaches of the agreement by Akebia, and ending the alliance early could spare it from spending hundreds of millions of dollars more on the drug.